OBJECTIVE: To perform an in depth evaluation of children, and thus provide a systematic method of managing children, who after infantile health screening, were categorized as suspected developmental delay. METHOD: 78 children referred to the Developmental Delay Clinic of Ilsan Hospital after suspected development delay on infantile health examinations were enrolled. A team comprised of a physiatrist, pediatrician and pediatric psychiatrist examined the patients. Neurological examination, speech and cognitive evaluation were done. Hearing tests and chromosome studies were performed when needed clinically. All referred children completed K-ASQ questionnaires. Final diagnoses were categorized into specific language impairment (SLI), global developmental delay (GDD), intellectual disability (ID), cerebral palsy (CP), motor developmental delay (MD) or autism spectrum disorder (ASD). RESULTS: 72 of the 78 patients were abnormal in the final diagnosis, with a positive predictive value of 92.3%. Thirty (38.4%) of the 78 subjects were diagnosed as GDD, 28 (35.8%) as SLI, 5 (6.4%) as ASD, 9 (12.5%) as MD, and 6 (7.6%) as normal. Forty five of the 78 patients had risk factors related to development, and 18 had a positive family history for developmental delay and/or autistic disorders. The mean number of abnormal domains on the K-ASQ questionnaires were 3.6 for ASD, 2.7 for GDD, 1.8 for SLI and 0.6 for MD. Differences between these numbers were statistically significant (p<0.05). CONCLUSION: Because of the high predictive value of the K-ASQ, a detailed evaluation is necessary for children suspected of developmental delay in an infantile health promotion system.
Cerebral Palsy ; Child ; Autism Spectrum Disorder ; Health Promotion ; Hearing Tests ; Humans ; Intellectual Disability ; Mass Screening ; Neurologic Examination ; Psychiatry ; Risk Factors ; Surveys and Questionnaires

BACKGROUND AND OBJECTIVES: The aim of this study was to investigate and compare the incidence and the characteristics of parameters of cervical vestibular-evoked myogenic potentials (cVEMPs) using air-conducted (AC) and bone-conducted (BC) stimulations in normal subjects. SUBJECTS AND METHOD: Twenty-four normal subjects (48 ears) with normal hearing and no previous history of dizziness were included. cVEMP responses were recorded by surface electrodes on sternocleidomastiod muscles in response to AC and BC stimuli sequentially. Variances of parameters, including thresholds, amplitudes and interaural amplitude difference ratios (IADR), were analyzed and compared. RESULTS: cVEMP responses were clearly observed in all 48 ears in both AC and BC cVEMP tests. There was no significant difference in latencies (p1 and n1). However, the thresholds in BC cVEMP testing were significantly lower than those in AC cVEMP testing, when compared to the maximum stimulation level. Interaural amplitude difference ratios showed no significant difference in between the two tests, although amplitudes at maximum stimulation intensity in BC cVEMP testing were significantly larger than those in AC cVEMP testing. CONCLUSION: This study shows that BC cVEMP testing shows lower thresholds compared to AC cVEMP testing in normal subjects, suggesting that the threshold value can be used as a parameter in detecting vestibular dysfunction in the clinic. Further studies in patients with various vestibular disorders are needed.
Dizziness ; Ear ; Electrodes ; Hearing ; Humans ; Incidence ; Muscles ; Vestibular Evoked Myogenic Potentials ; Vibration

OBJECTIVES: Vacuum-assisted breast biopsy (VABB) is a widely used technique for the diagnosis of breast lesions. It is carried out with local anesthesia, but procedural pain and stress are still problematic. Dexmedetomidine is a α-2 receptor agonist that can sedate without significant respiratory depression. The study aimed to report the effectiveness of sedation with monitored anesthesia care (MAC) using dexmedetomidine in VABB. METHODS: This was a retrospective chart review of patients who received VABB under MAC with dexmedetomidine. Forty-seven patients during the period of February 2015 to July 2016 were included. We collected data on patient characteristics, infusion drug and dose, induction to incision time, anesthetic, operation, and recovery time and other complications and vital signs. RESULTS: The mean operating time was 50.1 ± 24.9 minutes, and the anesthetic time was 71.2 ± 28.3 minutes. The mean time from induction to incision was 17.0 ± 5.2 minutes, and the recovery time was 20.1 ± 10.3 minutes. None of the patients needed an advanced airway management. Further, none of them showed hemodynamic instability. CONCLUSIONS: VABB was successfully performed with MAC using dexmedetomidine, and there was no respiratory depression or hemodynamic instability.
Airway Management ; Anesthesia ; Anesthesia, Local ; Biopsy ; Breast ; Dexmedetomidine ; Diagnosis ; Hemodynamics ; Humans ; Respiratory Insufficiency ; Retrospective Studies ; Vital Signs

Objectives: . To investigate the correlation of objective audiometry with user satisfaction as measured with the questionnaire scores. Methods: . Twenty patients with hearing loss, who agreed to wear a hearing aid and were referred for hearing aid fitting, were included in this prospective clinical study. All patients used the in-the-canal type of Wide7 hearing aid provided by BSL Co., Ltd. We performed the Korean version of the Hearing Handicap Inventory for the Elderly (K-HHIE) and the International Outcome Inventory for Hearing Aids (K-IOI-HA) before and 1, 3, and 6 months after wearing the hearing aid. We also performed pure tone audiometry (PTA), speech audiometry (SA), functional gain (FG), hearing in noise test (HINT), and central auditory processing disorder tests, such as frequency pattern test (CA-f), duration pattern test (CA-d), and dichotic test (CA-Di). Patients were divided into two groups (group A-HHIE, improved; group B-HHIE, same or worse) by comparing the score of K-HHIE before and 6 months after wearing the hearing aid. In the 6-month K-IOI-HA questionnaire, 21 points were considered as the average score. Based on this, we further divided patients into two groups (group A-IOI, >21 points; group B-IOI, ≤21 points). Results: . Group A-HHIE included six patients and group B-HHIE included 14 patients. In PTA, SA, HINT, CA-d, and CA-Di, group A-HHIE showed higher improvements than group B-HHIE, which were not statistically significant. Group A-IOI included 12 patients and group B-IOI included eight patients. No statistically significant difference was noted in the improvement of audiometric results over a period of 6 months after wearing the hearing aid between groups A-IOI and B-IOI. Conclusion . There were no significant and consistent audiometric results to reflect patient’s satisfaction with the hearing aid. Therefore, when analyzing the hearing aid-fitting outcome, both the objective audiometric tests and subjective questionnaire should be performed together for validating hearing aid performance.

Purpose: To evaluate the correlation between matrix metalloproteinase-9 (MMP-9) point-of-assay and clinical symptoms and signs of dry eye disease. Methods: We performed a retrospective study for patients diagnosed with dry eye. MMP-9 (InflammaDry) was performed on 235 patients. Patients were assessed using Schirmer test, corneal staining score, tear film breakup time (TBUT) and the Ocular Surface Disease Index (OSDI). Results: The score of Schirmer test was lower significantly in MMP-9 positive group than in MMP-9 negative group (for each 4.21 ± 5.80 mm, 5.96 ± 8.14 mm; p = 0.035). TBUT was shorter significantly in MMP-9 positive group than in MMP-9 negative group (for each 5.46 ± 4.06 s, 8.27 ± 4.75 s; p = 0.0008). The ratio of positive corneal stain (for each 83%, 31%) and OSDI even or greater than 13 (for each 80%, 75%) was significantly higher in MMP-9 positive group than in MMP-9 negative group (p = 0.00001, p = 0.0044). The value of MMP-9 point-of-care assay showed showed the negative correlation with Schirmer test (Rs = 0.383, p < 0.001), and TBUT (Rs = 0.310, p < 0.05), and showed the positive correlation with corneal staining score (Rs = 0.527, p < 0.001), OSDI (Rs = 0.510, p < 0.001). Conclusions MMP-9 point-of-assay accords with clinical symptoms and signs of Dry eye disease, and may be helpful in diagnosing Dry eye disease.

Purpose: To evaluate the correlation between matrix metalloproteinase-9 (MMP-9) point-of-assay and clinical symptoms and signs of dry eye disease. Methods: We performed a retrospective study for patients diagnosed with dry eye. MMP-9 (InflammaDry) was performed on 235 patients. Patients were assessed using Schirmer test, corneal staining score, tear film breakup time (TBUT) and the Ocular Surface Disease Index (OSDI). Results: The score of Schirmer test was lower significantly in MMP-9 positive group than in MMP-9 negative group (for each 4.21 ± 5.80 mm, 5.96 ± 8.14 mm; p = 0.035). TBUT was shorter significantly in MMP-9 positive group than in MMP-9 negative group (for each 5.46 ± 4.06 s, 8.27 ± 4.75 s; p = 0.0008). The ratio of positive corneal stain (for each 83%, 31%) and OSDI even or greater than 13 (for each 80%, 75%) was significantly higher in MMP-9 positive group than in MMP-9 negative group (p = 0.00001, p = 0.0044). The value of MMP-9 point-of-care assay showed showed the negative correlation with Schirmer test (Rs = 0.383, p < 0.001), and TBUT (Rs = 0.310, p < 0.05), and showed the positive correlation with corneal staining score (Rs = 0.527, p < 0.001), OSDI (Rs = 0.510, p < 0.001). Conclusions MMP-9 point-of-assay accords with clinical symptoms and signs of Dry eye disease, and may be helpful in diagnosing Dry eye disease.

Purpose: To evaluate the correlation between matrix metalloproteinase-9 (MMP-9) point-of-assay and clinical symptoms and signs of dry eye disease. Methods: We performed a retrospective study for patients diagnosed with dry eye. MMP-9 (InflammaDry) was performed on 235 patients. Patients were assessed using Schirmer test, corneal staining score, tear film breakup time (TBUT) and the Ocular Surface Disease Index (OSDI). Results: The score of Schirmer test was lower significantly in MMP-9 positive group than in MMP-9 negative group (for each 4.21 ± 5.80 mm, 5.96 ± 8.14 mm; p = 0.035). TBUT was shorter significantly in MMP-9 positive group than in MMP-9 negative group (for each 5.46 ± 4.06 s, 8.27 ± 4.75 s; p = 0.0008). The ratio of positive corneal stain (for each 83%, 31%) and OSDI even or greater than 13 (for each 80%, 75%) was significantly higher in MMP-9 positive group than in MMP-9 negative group (p = 0.00001, p = 0.0044). The value of MMP-9 point-of-care assay showed showed the negative correlation with Schirmer test (Rs = 0.383, p < 0.001), and TBUT (Rs = 0.310, p < 0.05), and showed the positive correlation with corneal staining score (Rs = 0.527, p < 0.001), OSDI (Rs = 0.510, p < 0.001). Conclusions MMP-9 point-of-assay accords with clinical symptoms and signs of Dry eye disease, and may be helpful in diagnosing Dry eye disease.

Purpose: To evaluate the correlation between matrix metalloproteinase-9 (MMP-9) point-of-assay and clinical symptoms and signs of dry eye disease. Methods: We performed a retrospective study for patients diagnosed with dry eye. MMP-9 (InflammaDry) was performed on 235 patients. Patients were assessed using Schirmer test, corneal staining score, tear film breakup time (TBUT) and the Ocular Surface Disease Index (OSDI). Results: The score of Schirmer test was lower significantly in MMP-9 positive group than in MMP-9 negative group (for each 4.21 ± 5.80 mm, 5.96 ± 8.14 mm; p = 0.035). TBUT was shorter significantly in MMP-9 positive group than in MMP-9 negative group (for each 5.46 ± 4.06 s, 8.27 ± 4.75 s; p = 0.0008). The ratio of positive corneal stain (for each 83%, 31%) and OSDI even or greater than 13 (for each 80%, 75%) was significantly higher in MMP-9 positive group than in MMP-9 negative group (p = 0.00001, p = 0.0044). The value of MMP-9 point-of-care assay showed showed the negative correlation with Schirmer test (Rs = 0.383, p < 0.001), and TBUT (Rs = 0.310, p < 0.05), and showed the positive correlation with corneal staining score (Rs = 0.527, p < 0.001), OSDI (Rs = 0.510, p < 0.001). Conclusions MMP-9 point-of-assay accords with clinical symptoms and signs of Dry eye disease, and may be helpful in diagnosing Dry eye disease.